Transgene Appoints Philippe Archinard As New Chief Executive Officer
December 07 2004 - 11:01PM
PR Newswire (US)
Transgene Appoints Philippe Archinard As New Chief Executive
Officer STRASBOURG, France, Dec. 8 /PRNewswire-FirstCall/ --
Transgene (Nasdaq: TRGNY; Euronext: FR0005175080) announced today
that its Board of Directors chaired by Dr. Christophe Merieux
yesterday appointed Philippe Archinard as the new Chief Executive
Officer ("CEO") and Board Director. He replaces Jean-Francois
Carmier, who is leaving Transgene for personal reasons. The Board
of Directors expressed its thanks to Jean-Francois Carmier for his
contribution to the development of Transgene (the "Company"). "We
are very happy to welcome Philippe Archinard to Transgene," stated
Dr. Christophe Merieux, Chairman of Transgene. "Philippe's
background as former CEO of the biotechnology company Innogenetics
and his international experience will accelerate our Company's
developments." Philippe Archinard, 45, began his career with
bioMerieux where he held various positions for 15 years in France
and the United States, including CEO of the U.S. operations. Since
March 2000, he has served as Chief Executive Officer of
Innogenetics. He holds a chemical engineering degree and a PhD in
biochemistry from Lyon University, and has completed the PMD
program at the Harvard Business School. In addition, the Board of
Directors was informed by the principal shareholder of Transgene of
its commitment to cover Transgene's cash needs until the end of
2005 unless another financing option is adopted during this
timeframe, in order for the new CEO to develop and implement his
strategy. About Transgene Transgene, based in Strasbourg, France,
is a biopharmaceutical company dedicated to the discovery and
development of therapeutic vaccines, immunotherapy products, and
delivery technologies for the treatment of diseases for which there
is no cure or adequate treatment at present, with a focus on the
treatment of cancer. Transgene has five products in clinical
development, two of which are in Phase II clinical trials, two in
Phase I/II clinical trials and one that has completed a Phase I
clinical trial. Transgene's proprietary vector technology platform
consists of adenoviral and poxviral families. This press release
contains forward-looking information regarding the funding of
Transgene's operations through the end of 2005. This information
reflects statements made by the Company's principal shareholder at
the Board of Directors meeting on December 7, 2004. It is not a
guaranty by the Company of on-going operations or future
performance. DATASOURCE: Transgene CONTACT: Transgene,
+33-3-88-27-91-01; Michael Long, Cohn & Wolfe, +1-415-365-8523,
for Transgene; Tiphaine Hecketsweiler, Image 7, +33-1-53-70-74-59,
for Transgene
Copyright